The GC of MRNA, Lori M. Henderson has sold close to 6,600 shares of the company stocks in a 27th May transaction. The average price of the stocks was $174.20, with the total transaction coming to $1.14 million. After the transaction, the GC has ownership of about 7,501 shares of the company stocks, which has a total valuation of $1.3 million. The documentation for the transaction is stored with the SEC.
The Quarterly Estimates of MRNA
The stocks of MRNA traded on Friday at $5.07. The moving average price of the company over a period of 50 days is $163.05, with the moving average price of the company over a period of 200 days is $143.24. The debt-to-equity ratio is 0.04, with a 1.39 current ratio, and a 1.33 quick ratio. The year low of the company is $53.35, with a year high of around $189.26. The market cap of the firm is $74.13 billion, with a 143.63 PE ratio.
MRNA previously updated its quarterly results on the 6th of May. The EPS reported by the company during this period was $2.84, which was more than the consensus estimate of $2.04. The revenue generated by the company over the period was $1.94 billion, which was slightly less than the consensus estimate of $2.48 billion. The net margin of the company is 21.90%, with a 19.76% return on equity.
There have been quite a few research equities that have commented on the stocks of MRNA. SVB Leerink has already reiterated its rating of sell in an 18th April research report. The Bank of America has reiterated its rating of sell with a price target of $140 in a 26th February research note.
Three of the investment analysts have already given the company a rating of sell, while seven others have issued the company a rating of hold. Eight of the investment analysts have issued the company with a rating of buy. Currently, MRNA has a hold rating with a $162.88 price target.
